Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma


Forty-nine patients were treated with either 3×75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.

This is a preview of subscription content, log in to check access.


  1. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM (1986) Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12: 447–454

  2. Buchali K, Correns HJ, Schnorr D, Schuerer M, Sydow K, Lips H (1984) Therapie mit 89-Sr bei Knochenmetastasen von Prostatakarzinomen. In: Hoefer R (ed). Radioaktive Isotope in Klinik und Forschung 16. Egermann, Vienna, pp 151–157

  3. Correns HJ, Mebel M, Buchali K, Schnorr D, Seidel C, Mitterlechner E (1979) 89-Strontium therapy of bone metastases of carcinoma of the prostatic gland. Eur J Nucl Med 4: 33–34

  4. Correns HJ, Buchali K, Sydow K, Schuerer M, Schnorr D, Richter K (1982) Nuklearmedizinische Therapie von Metastasen des Skelettsystems. In: Schwartz D 19th Symposion Nuklearmedizin, Reinhardsbrunn, Schriftenreihe, Berlin pp 35–40

  5. Correns HJ, Buchali K, Schnorr D, Lips H, Sydow K, Schuerer M, Johannsen B (1986) On the efficacy of Strontium-89 therapy. Preliminary evaluation of a double-blind study. In: Winkler C (ed) Nuclear medicine in clinical oncology. Springer, Berlin Heidelberg New York Tokyo pp 345–347

  6. Cox DR (1972) Regression models and life tables. J R Statist Soc B 34: 187–220

  7. Firusian N, Mellin P, Schmidt CG (1976) Results of 89 Strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urology 116: 764

  8. Firusian N (1979) Radionuklidbehandlung von Skelettmetastasen. Nuklearmediziner 4: 314–327

  9. Kaul A, Oeff K, Roedler HD, Vogelsang T (1973) Die Strahlenbelastung von Patienten bei der nuklearmedizinischen Anwendung offener radioaktiver Stoffe. Informationsdienst Nuclearmedizin Berlin

  10. Kutzner J, Grimm W, Hahn K (1977) Interne Strahlentherapie mit Strontium 89 bei metastasenbedingten Schmerzzustaenden. Muench Med Wochenschr 119: 1251

  11. Kutzner J, Grimm W, Brod KH, Roesler A (1982) Die Yttrium-90 Therapie von Knochenmetastasen. Dtsch Med Wochenschr 107: 1360–1361

  12. Langhammer H, Sintermann R, Hoer G, Pabst HW (1978) Serial bone scintigraphy for assessing the effectiveness of treatment of osseous metastases from prostatic cancer. J Nucl Med 17: 87–91

  13. Levenson RM, Sauerbrunn BJL, Bates HR, Newman RD, Eddy JL, Ihde DC (1983) Comparative value of bone scintigraphy and radiography in monitoring tumor response in systematically treated prostatic carcinoma. Radiology 146: 513–518

  14. Schmid L, Langhammer H, Braun J, Oberdorfer M, Steuer G, Herz R, Pabst HW (1982) Skelettszintigraphische und radiologische Befunde bei 403 Prostatakarzinompatienten in Primaerdiagnostik, Verlaufs- und Therapiekontrolle. In: Hoefer R (ed) Radioaktive Isotope in Klinik und Forschung 15. Egermann, Vienna pp 349–360

  15. Silberstein EB, Williams C (1985) Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26: 345–348

  16. Snyder WS, Ford MR, Warner GG, Watson SB (1975) MIRD pamphlet No. 11. Soc Nucl Med

Download references

Author information

Correspondence to Klaus Buchali.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Buchali, K., Correns, H., Schuerer, M. et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14, 349–351 (1988). https://doi.org/10.1007/BF00254382

Download citation

Key words

  • Radionuclide therapy
  • Skeletal metastases
  • 89-strontium